Treatment with Ω-3 fatty acids but not exendin-4 improves hepatic steatosis

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 10, 2010, Pages 1245-1252

  Bulchandani, Deepti G ^a   Nachnani, Jagdish S ^b,d   Nookala, Anupama ^b   Naumovitch, Christina ^b   Herndon, Betty ^c   Molteni, Agostino ^b,c   Quinn, Tim ^c   Alba, Laura M ^b,d  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^c Research Lab M3 202   (United States)

^d ST LUKE S HOSPITAL   (United States)

Author keywords

adipocytokines; fish oil; nonalcoholic fatty liver disease

Indexed keywords

ADIPOCYTOKINE; CYTOCHROME P450 2E1; CYTOCHROME P450 4A1; EXENDIN 4; LIVER ENZYME; OMEGA 3 FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; INSULIN RESISTANCE; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RAT;

ADIPOKINES; ALKANE 1-MONOOXYGENASE; ANIMALS; BODY WEIGHT; CORN OIL; CYTOCHROME P-450 CYP2E1; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; FATTY ACIDS, OMEGA-3; FATTY LIVER; FISH OILS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER; MALE; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; VENOMS;

EID: 77957560313     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32833b257a     Document Type: Article

References (36)

1. Wieckowska A, Feldstein AE. Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr 2005;17:636-641.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
3. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
4. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 2008;103:1036-1042.
5. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121.
6. Day CP, James OF. Steatohepatitis: a tale of two hits? Gastroenterology 1998;114:842-845.
7. Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2008;14:22-28.
8. Sanyal AJ. Insulin resistance and nonalcoholic steatohepatitis: fat or fiction? Am J Gastroenterol 2001;96:274-276.
9. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
10. Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989;30:785-807.
11. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 2006;17:387-393.
12. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997;65:1645S-1654S.
13. Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006;29:471.
14. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002;87:1282-1290.
15. De Leon DD, Crutchlow MF, Ham JY, Stoffers DA. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol 2006;38:845-859.
16. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993;268:19650-19655.
17. Li L, Yang G, Li Q, Tan X, Liu H, Tang Y, Boden G. Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obes Metab 2008;10:921-930.
18. Nanji AA. Animal models of nonalcoholic fatty liver disease and steatohepatitis. Clin Liver Dis 2004;8:559-574.
19. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000;105:1067-1075.
20. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006;43:173-181.
21. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3-16.
22. Desmet V. Histological classification of chronic hepatitis. Acta gastro-enterologica Belgica 1997;60:259-267.
23. Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2009;25:230-237.
24. Lam BP, Younossi ZM. Treatment regimens for non-alcoholic fatty liver disease. Ann Hepatol 2009;8(Suppl 1):S51-S59.
25. Schmocker C, Weylandt KH, Kahlke L, Wang J, Lobeck H, Tiegs G, et al. Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. Hepatology 2007;45:864-869.
26. Weylandt KH, Kang JX. Rethinking lipid mediators. Lancet 2005;366:618-620.
27. El-Badry AM, Graf R, Clavien PA. Omega 3-Omega 6: what is right for the liver? J Hepatol 2007;47:718-725.
28. Sekiya M, Yahagi N, Matsuzaka T, Najima Y, Nakakuki M, Nagai R, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003;38:1529-1539.
29. Larter CZ, Yeh MM, Cheng J, Williams J, Brown S, dela Pena A, et al. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. J Gastroenterol Hepatol 2008;23:267-275.
30. Eritsland J. Safety considerations of polyunsaturated fatty acids. Am J Clin Nutr 2000;71:197S-201S.
31. Rizki G, Arnaboldi L, Gabrielli B, Yan J, Lee GS, Ng RK, et al. Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1. J Lipid Res 2006;47:2280-2290.
32. Cao H, Maeda K, Gorgun C, Kim HJ, Park SY, Shulman GI, et al. Regulation of metabolic responses by adipocyte/macrophage fatty acid-binding proteins in leptin-deficient mice. Diabetes 2006;55:1915.
33. Yao ZM, Vance DE. The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. J Biol Chem 1988;263:2998-3004.
34. Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006;26:1015-1017.
35. Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, Crabb DW. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003;37:544-550.
36. Ringseis R, Eder K. Effects of dietary fat and oxidized cholesterol on gene expression in rat liver as assessed by cDNA expression array analysis. Eur J Nutr 2005;44:231-241.